Q2 2026 Results Show NAV Decline, Increased Non-Accruals Despite Fee Cuts & Buybacks
CCAP is trading near its 52-week low of $10.64 (5.5% above the low).
Summary
Crescent Capital BDC reported a decline in NAV and an increase in non-accrual investments for Q2 2026, despite implementing fee reductions and share repurchases.
Key Events · Earnings and Guidance · CCAP
-
Net Asset Value Declined
Net Asset Value (NAV) per share decreased to $17.82 as of June 30, 2026, down from $19.10 at December 31, 2025.
-
Net Decrease in Net Assets
The company reported a net decrease in net assets resulting from operations of $18.76 million for the six months ended June 30, 2026.
-
Non-Accrual Investments Increased
Non-accrual investments rose to 4.8% of total debt investments at cost as of June 30, 2026, up from 4.1% at December 31, 2025, indicating deteriorating portfolio quality.
-
Management Fee Reductions Implemented
Effective April 1, 2026, the base management fee was reduced from 1.25% to 1.00% and income/capital gains incentive fees were reduced from 17.5% to 15.0%.
Analysis · CCAP · Unknown
Crescent Capital BDC, Inc. reported a continued decline in Net Asset Value per share and an increase in non-accrual investments, signaling ongoing deterioration in portfolio health. While management proactively reduced base and incentive fees and executed share repurchases, these actions were not enough to offset the negative financial performance. The increase in non-accrual loans is a key concern for a BDC, indicating potential future credit losses.
At the time of this filing, CCAP was trading at $11.23 on NASDAQ in the Unknown sector, with a market capitalization of approximately $430.4M. The 52-week trading range was $10.64 to $16.04. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.